| Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is … TA Eyre, AA Kirkwood, J Wolf, C Hildyard, C Mercer, H Plaschkes, ... British journal of haematology 187 (2), 185-194, 2019 | 64 | 2019 |
| Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia AS Gunawan, DP McLornan, B Wilkins, K Waghorn, Y Hoade, NCP Cross, ... Haematologica 102 (6), e238, 2017 | 44 | 2017 |
| Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no … TA Eyre, N Martinez‐Calle, C Hildyard, DW Eyre, H Plaschkes, J Griffith, ... Journal of internal medicine 285 (6), 681-692, 2019 | 40 | 2019 |
| Restriction of memory B cell differentiation at the germinal center B cell positive selection stage A Toboso-Navasa, A Gunawan, G Morlino, R Nakagawa, A Taddei, ... Journal of Experimental Medicine 217 (7), 2020 | 33 | 2020 |
| PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma A D’Avola, N Legrave, M Tajan, P Chakravarty, RL Shearer, HW King, ... The Journal of clinical investigation 132 (9), 2022 | 28 | 2022 |
| Infection-related morbidity and mortality among older patients with DLBCL treated with full-or attenuated-dose R-CHOP TA Eyre, W Wilson, AA Kirkwood, J Wolf, C Hildyard, H Plaschkes, ... Blood Advances 5 (8), 2229-2236, 2021 | 26 | 2021 |
| Ruxolitinib for the treatment of essential thrombocythemia A Gunawan, P Harrington, N Garcia-Curto, D McLornan, D Radia, ... HemaSphere 2 (4), e56, 2018 | 18 | 2018 |
| Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma S Booth, H Plaschkes, AA Kirkwood, A Gibb, P Horgan, C Higham, ... Blood Advances 4 (18), 4337-4346, 2020 | 15 | 2020 |
| Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R‐CHOP T Eyre, N Martinez-Calle, C Hildyard, D Eyre, H Plaschkes, J Griffith, ... British Journal of Haematology 186 (4), 2019 | 12 | 2019 |
| Regulation of BCR-mediated Ca2+ mobilization by MIZ1-TMBIM4 safeguards IgG1+ GC B cell–positive selection L Zhang, A Toboso-Navasa, A Gunawan, A Camara, R Nakagawa, ... Science immunology 9 (94), eadk0092, 2024 | 3 | 2024 |
| PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma A D’Avola, N Legrave, M Tajan, P Chakravarty, RL Shearer, HW King, ... bioRxiv, 2021.11. 11.468272, 2021 | 2 | 2021 |
| Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience C Bourlon, KE Bailey, R Benjamin, K Cuthill, A Gunawan, M Kazmi, ... Blood 142, 4971, 2023 | 1 | 2023 |
| Achievement of complete hematological remission and reversal of high HTLV-1 viral loads with anti CCR-4 monoclonal antibody administration in Afro caribbean patients with … P Fields, M Demontis, L Cook, S Marks, D Wrench, A Gunawan, ... Blood, The Journal of the American Society of Hematology 124 (21), 5474-5474, 2014 | 1 | 2014 |
| Consideration of Tandem Autologous Stem Cell Transplant for Patients with Multiple Myeloma-a Large UK Single Centre Retrospective Analysis A Corby, K Bailey, A Gunawan, K Cuthill, J Jones, M Cuadrado, ... Blood 144, 7850, 2024 | | 2024 |
| Safety and Efficacy of Dara-VTD Induction and Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients Presenting with Renal Failure-a Tertiary Centre … A Maraj, K Bailey, A Batool, R Benjamin, S Bowcock, K Bramham, ... Blood 144, 7076, 2024 | | 2024 |
| P-338 High Frequency of Electrolyte Derangement and Low Frequency of Transfusion Requirement Post Melphalan Autologous Bone Marrow Transplant–a Single Center Experience S Balakrishnan, C Gahan, M Kenyon, D Thurgood, G Bruce, T Price, ... Clinical Lymphoma Myeloma and Leukemia 24, S228-S229, 2024 | | 2024 |
| P-393 A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London … D Yildiz, S Kahrimanovic, Y Salam, K Cuthill, K Bailey, R Benjamin, ... Clinical Lymphoma Myeloma and Leukemia 24, S260-S261, 2024 | | 2024 |
| P-218 Inadequacy of MYC Gene Expression Alone as a Risk Determinant in Multiple Myeloma–the Importance of Associated MIZ1 Expression A Simpson, A Gunawan, D Calado, MM Karimi, R Benjamin Clinical Lymphoma Myeloma and Leukemia 24, S163, 2024 | | 2024 |
| P-337 Lower Utilisation of Autologous Stem Cell Transplant in Patients With Multiple Myeloma From Black Caribbean and Black African Ethnic Groups in the UK–a Single Center … A Gunawan, D Adebambo, B Jones, K Bailey, K Cuthill, R Benjamin, ... Clinical Lymphoma Myeloma and Leukemia 24, S228, 2024 | | 2024 |
| P-087 Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience PT Feixas, C Cox, X Peer, K Cuthill, R Benjamin, A Gunawan, ... Clinical Lymphoma Myeloma and Leukemia 24, S92, 2024 | | 2024 |
Graham CollinsOxford在 ouh.nhs.uk 的电子邮件经过验证
